75 patents
Page 4 of 4
Utility
Polynucleotides encoding relaxin
3 Aug 20
The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.
Barry Ticho, Nadege Briancon-Eris, Zhinan Xia, Athanasios Dousis, Seymour de Picciotto, Vladimir Presnyak, Stephen Hoge, Iain Mcfadyen, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
Filed: 1 Jul 18
Utility
Human cytomegalovirus RNA vaccines
20 Jul 20
The disclosure describes HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Shinu John, Kambiz Mousavi
Filed: 23 Jun 19
Utility
Nucleic acid vaccines
13 Jul 20
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (NAVs) comprising polynucleotide molecules encoding one or more antigens.
Giuseppe Ciaramella, Axel Bouchon, Eric Yi-Chun Huang
Filed: 26 Jul 18
Utility
CHIKV RNA vaccines
6 Jul 20
Aspects of the disclosure relate to nucleic acid vaccines.
Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
Filed: 14 Jun 18
Utility
HPIV3 RNA vaccines
6 Jul 20
The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Sunny Himansu
Filed: 27 Mar 19
Utility
Betacoronavirus mRNA vaccine
6 Jul 20
The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Sunny Himansu
Filed: 27 Feb 20
Utility
Modified polynucleotides for the production of secreted proteins
6 Jul 20
A pharmaceutical composition which has a plurality of lipid nanoparticles that has a mean particle size of between 80 nm and 160 nm and contains a modified mRNA encoding a polypeptide.
Antonin De Fougerolles, Justin Guild
Filed: 11 Jun 19
Utility
Human cytomegalovirus vaccine
29 Jun 20
The disclosure relates to HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Shinu John
Filed: 18 Apr 19
Utility
Chikungunya virus RNA vaccines
8 Jun 20
The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof.
Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks, Sayda Mahgoub Elbashir
Filed: 19 Sep 18
Utility
High purity RNA compositions and methods for preparation thereof
18 May 20
The invention relates to improved RNA compositions for use in therapeutic applications.
Stephen Hoge, William Issa, Edward J. Miracco, Jennifer Nelson, Amy E. Rabideau, Gabor Butora
Filed: 5 Jun 18
Utility
Zika virus MRNA vaccines
18 May 20
Provided herein, in some embodiments, are Zika virus RNA vaccines and methods of producing an antigen-specific immune response in a subject.
Giuseppe Ciaramella, Sunny Himansu
Filed: 13 Sep 18
Utility
Polynucleotides encoding interleukin-12 (IL12) and uses thereof
11 May 20
The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12.
Joshua Frederick, Susannah Hewitt, Ailin Bai, Stephen Hoge, Vladimir Presnyak, Iain Mcfadyen, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
Filed: 14 Nov 18
Utility
Ion exchange purification of mRNA
16 Mar 20
The current landscape for preparative chromatographic RNA purification uses reversed phase HPLC, but this technique presents many issues with process scale up and ion exchange for preparative purification has only been used for short RNAs.
William Joseph Issa, Joseph Louis Barberio, John Grant Aunins, Noubar B. Afeyan
Filed: 13 Mar 14
Utility
In vivo production of proteins
9 Mar 20
The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.
Antonin De Fougerolles, Justin Guild
Filed: 13 Jun 19
Utility
Modified polynucleotides for the production of secreted proteins
2 Mar 20
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
Antonin De Fougerolles, Justin Guild
Filed: 11 Jun 19